2010 American Heart Association

S850 Circulation November 2, 2010
Disclosures
Guidelines Part 12: Cardiac Arrest in Special Situations: Writing Group Disclosures
Writing Group
Member Employment Research Grant
Terry L. Vanden
Hoek
Laurie J.
Morrison
The University of
Chicago-Associate
Professor
St. Michaels Clinician
scientist
Michael Shuster Self-employed–emergency
physician
Michael Donnino Harvard Medical Faculty
Physicians–Physician
Elizabeth Sinz Penn State Hershey
Medical Center–Professor
of Anesthesiology and
Neurosurgery;
AHA–Associate Science
Editor
Eric J. Lavonas Rocky Mountain Poison &
Drug Center; (RMPDC)
Denver, Colo. Associate
Director
Farida M.
Jeejeebhoy
Self employed
cardiologist, affiliate with
University Health
Network/Mt Sinai and
University of Toronto
Other
Research
Support
Speakers’ Bureau/
Honoraria
Ownership
Interest
Consultant/
Advisory Board Other
*Vanden Hoek, Principal Investigator, Department
of Defense, Office of Naval Research, �Proteomic
Development of Molecular Vital Signs: Mapping a
Mitochondrial Injury Severity Score to Triage and
Guide Resuscitation of Hemorrhagic Shock.�
Research grant awarded to the University of
Chicago
None None None None None
None None None None None None
None None None None None None
†Corticosteroids in Post-arrest Shock (American
Heart Association, Scientist Development Grant);
Thiamine as a Metabolic Resuscitator in Septic
Shock (NIH pending); *Statins in Sepsis (Eleanor
Shore) Clinical Correlates to Influenza Genome
(NIH); Thiamine Deficiency in Critically Ill
(Harvard Medical School/NIH); Thiamine for
Congestive Heart Failure (Baystate Incubator
Fund-NON-industry, academic hospital funding)
None None None None None
None None None None None None
†RMPDC performed research related to
hydroxocobalamin prior to its licensure in the
United States. This occurred prior to my arrival
at RMPDC. RMPDC-DH performed work related
to the development of hydroxocobalamin
(CyanoKit, Dey LP) as a cyanide antidote.
Various projects were completed in 2001, 2005,
and 2006. Some of the sponsors of this
research (EMD; Merck KGA) either no longer
exist or no longer have an interest in
hydroxocobalamin. I was not involved in this
research, which was performed long before my
arrival. RMPDC-DH does not have any current or
pending hydroxocobalamin-related projects.
Neither I nor any other DHHA employee derives
personal financial benefit from these
relationships. I don’t get a bonus of any sort. My
salary is supported by general institutional funds
and an unrelated research endowment. Also, my
performance evaluation is not related the
performance of any of these contracts. My role:
PI on one portion of the project, collaborator on
the rest 2008–2009 (ongoing)
None None None None None
None None None None None None
Andrea Gabrielli University of
†NIH-Biomarkers in Traumatic Brain Injury None None None None None
Florida–Professor of
Anesthesiology and
Surgery
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the
Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person
receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share
of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the
preceding definition.
*Modest.
†Significant.
Downloaded from
circ.ahajournals.org at NATIONAL TAIWAN UNIV on October 18, 2010